Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/11000/31404
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.authorAgulló, Laura-
dc.contributor.authorAguado, Isidro-
dc.contributor.authorMuriel, Javier-
dc.contributor.authorMargarit, César-
dc.contributor.authorGómez, Alba-
dc.contributor.authorEscorial, Mónica-
dc.contributor.authorSánchez, Astrid-
dc.contributor.authorFernández, Alicia-
dc.contributor.authorPeiró, Ana-
dc.contributor.otherDepartamentos de la UMH::Farmacología, Pediatría y Química Orgánicaes_ES
dc.date.accessioned2024-02-09T16:35:15Z-
dc.date.available2024-02-09T16:35:15Z-
dc.date.created2023-
dc.identifier.citationInternational Journal of Molecular Sciences . 2023 Jun 28;24(13):10754es_ES
dc.identifier.issn1422-0067-
dc.identifier.urihttps://hdl.handle.net/11000/31404-
dc.description.abstractInterindividual variability in analgesic response is at least partly due to well-characterized polymorphisms that are associated with opioid dosing and adverse outcomes. The Clinical Pharmacogenetics Implementation Consortium (CPIC) has put forward recommendations for the CYP2D6 phenotype, but the list of studied drug-gene pairs continues to grow. This clinical trial randomized chronic pain patients (n = 60), referred from primary care to pain unit care into two opioid prescribing arms, one guided by CYP2D6, μ-opioid receptor (OPRM1), and catechol-O-methyl transferase (COMT) genotypes vs. one with clinical routine. The genotype-guided treatment reduced pain intensity (76 vs. 59 mm, p < 0.01) by improving pain relief (28 vs. 48 mm, p < 0.05), increased quality of life (43 vs. 56 mm p < 0.001), and lowered the incidence of clinically relevant adverse events (3 [1-5] vs. 1 [0-2], p < 0.01) and 42% opioid dose (35 [22-61] vs. 60 [40-80] mg/day, p < 0.05) as opposed to usual prescribing arm. The final health utility score was significantly higher (0.71 [0.58-0.82] vs. 0.51 [0.13-0.67] controls, p < 0.05) by improving sleepiness and depression comorbidity, with a significant reduction of 30-34% for headache, dry mouth, nervousness, and constipation. A large-scale implementation analysis could help clinical translation, together with a pharmaco-economic evaluation.es_ES
dc.formatapplication/pdfes_ES
dc.format.extent15es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectpharmacogeneticses_ES
dc.subjectCYP2D6es_ES
dc.subjectOPRM1es_ES
dc.subjectCOMTes_ES
dc.subjectopioidses_ES
dc.subjectchronic paines_ES
dc.titlePharmacogenetic Guided Opioid Therapy Improves Chronic Pain Outcomes and Comorbid Mental Health: A Randomized, Double-Blind, Controlled Studyes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.contributor.instituteInstitutos de la UMH::Instituto de Bioingenieríaes_ES
dc.relation.publisherversion10.3390/ijms241310754.es_ES
Aparece en las colecciones:
Artículos Farmacología, Pediatría y Química Orgánica


Vista previa

Ver/Abrir:
 Pharmacogenetic Guided Opioid Therapy Improves Chronic.pdf

1,35 MB
Adobe PDF
Compartir:


Creative Commons La licencia se describe como: Atribución-NonComercial-NoDerivada 4.0 Internacional.